140 related articles for article (PubMed ID: 33676770)
1. PARD3-ALK: A novel ALK fusion gene identified in a patient with lung adenocarcinoma.
Yang L; Zhao W; Zhu H; Li X; Zhao G
Lung Cancer; 2021 Apr; 154():219-220. PubMed ID: 33676770
[No Abstract] [Full Text] [Related]
2. MPRIP-ALK, a Novel ALK Rearrangement That Responds to ALK Inhibition in NSCLC.
Fang W; Gan J; Hong S; Lu F; Zhang L
J Thorac Oncol; 2019 Jul; 14(7):e148-e151. PubMed ID: 31235041
[No Abstract] [Full Text] [Related]
3. TMED2-ALK, a Novel ALK Fusion Gene Identified in a Patient With Lung Adenocarcinoma.
Mao W; Chen R; Zhang J; Zheng M
J Thorac Oncol; 2020 Mar; 15(3):e37-e39. PubMed ID: 32093858
[No Abstract] [Full Text] [Related]
4. PLB1-ALK: A novel head-to-head fusion gene identified by next-generation sequencing in a lung adenocarcinoma patient.
Wang B; Chen R; Wang C; Chen H; Zhong D
Lung Cancer; 2021 Mar; 153():176-178. PubMed ID: 33483162
[No Abstract] [Full Text] [Related]
5. Next-generation Sequencing Identified a Novel WDPCP-ALK Fusion Sensitive to Crizotinib in Lung Adenocarcinoma.
He Z; Wu X; Ma S; Zhang C; Zhang Z; Wang S; Yu S; Wang Q
Clin Lung Cancer; 2019 Sep; 20(5):e548-e551. PubMed ID: 31281052
[No Abstract] [Full Text] [Related]
6. SMPD3-ALK: A novel ALK fusion gene in lung adenocarcinoma.
Liang Y; Wang Y; Wang W; Zhao J; Xu M; Zheng M
Clin Genet; 2021 Mar; 99(3):488-489. PubMed ID: 33556194
[TBL] [Abstract][Full Text] [Related]
7. SRBD1-ALK, a Novel ALK Fusion Gene Identified in an Adenocarcinoma Patient by Next-Generation Sequencing.
Hou X; Xu H; Chen L
J Thorac Oncol; 2019 Apr; 14(4):e72-e73. PubMed ID: 30922581
[No Abstract] [Full Text] [Related]
8. Identification and Development of a Lung Adenocarcinoma PDX Model With STRN-ALK Fusion.
Ren H; Hou X; Eiken PW; Zhang J; Pierson KE; Nair AA; Davila JI; Kovarikova H; Jang JS; Johnson SH; Molina JR; Marks RS; Yang P; Yi JE; Mansfield AS; Jen J
Clin Lung Cancer; 2019 Mar; 20(2):e142-e147. PubMed ID: 30581091
[No Abstract] [Full Text] [Related]
9. The clinical responses of TNIP2-ALK fusion variants to crizotinib in ALK-rearranged lung adenocarcinoma.
Feng T; Chen Z; Gu J; Wang Y; Zhang J; Min L
Lung Cancer; 2019 Nov; 137():19-22. PubMed ID: 31521978
[TBL] [Abstract][Full Text] [Related]
10. Coexistence of a Novel PRKCB-ALK, EML4-ALK Double-Fusion in a Lung Adenocarcinoma Patient and Response to Crizotinib.
Luo J; Gu D; Lu H; Liu S; Kong J
J Thorac Oncol; 2019 Dec; 14(12):e266-e268. PubMed ID: 31757376
[No Abstract] [Full Text] [Related]
11. A novel 5'ALK fusion identified by next generation sequencing and validated by IHC in a patient with lung adenocarcinoma.
He Z; Zhu X; Zeng Q; Yu Z
Lung Cancer; 2021 Aug; 158():164-165. PubMed ID: 34120772
[No Abstract] [Full Text] [Related]
12. DNA and RNA sequencing revealed a complex intergenic-ALK fusion in a lung adenocarcinoma patient who responded to TKI therapy.
Zhang J; Huang J; Li Q; Lin H; Luo Z; Chen R
Lung Cancer; 2021 Sep; 159():171-174. PubMed ID: 34266695
[No Abstract] [Full Text] [Related]
13. Coexistence of a novel RGS18 downstream intergenic region ALK fusion and a THUMPD2-ALK fusion in a lung adenocarcinoma patient and response to crizotinib.
Wang YL; Wu ZZ; Zhang HR; Chen DS; Zhao X
Lung Cancer; 2021 Apr; 154():216-218. PubMed ID: 33637344
[No Abstract] [Full Text] [Related]
14. [Clinical features of 54 cases of lung adenocarcinomas with c-ROS oncogene 1 fusion].
Cao H; Zheng J; Zhao J; Guo XJ; Zhou JY; Ding W; Zhou JY
Zhonghua Jie He He Hu Xi Za Zhi; 2020 Feb; 43(2):120-125. PubMed ID: 32062881
[No Abstract] [Full Text] [Related]
15. Concomitant EGFR Mutation and EML4-ALK Rearrangement in Lung Adenocarcinoma Is More Frequent in Multifocal Lesions.
Fan J; Dai X; Wang Z; Huang B; Shi H; Luo D; Zhang J; Cai W; Nie X; Hirsch FR
Clin Lung Cancer; 2019 Jul; 20(4):e517-e530. PubMed ID: 31138506
[TBL] [Abstract][Full Text] [Related]
16. Novel NLRC4-ALK and EML4-ALK double fusion mutations in a lung adenocarcinoma patient: A case report.
Wu X; Wang W; Zou B; Li Y; Yang X; Liu N; Ma Q; Zhang X; Wang Y; Li D
Thorac Cancer; 2020 Jun; 11(6):1695-1698. PubMed ID: 32212216
[TBL] [Abstract][Full Text] [Related]
17. A Novel Intergenic Region between CENPA and DPYSL5-ALK Exon 20 Fusion Variant Responding to Crizotinib Treatment in a Patient with Lung Adenocarcinoma.
Fei X; Zhu L; Zhou H; Qi C; Wang C
J Thorac Oncol; 2019 Sep; 14(9):e191-e193. PubMed ID: 31445731
[No Abstract] [Full Text] [Related]
18. A novel HIP1-ALK fusion variant in lung adenocarcinoma showing resistance to Crizotinib.
Li M; Tang Q; Chen S; Wang Y
Lung Cancer; 2021 Jan; 151():98-100. PubMed ID: 33280926
[No Abstract] [Full Text] [Related]
19. VIT-ALK, a Novel Alectinib-Sensitive Fusion Gene in Lung Adenocarcinoma.
Hu S; Li Q; Peng W; Feng C; Zhang S; Li C
J Thorac Oncol; 2018 May; 13(5):e72-e74. PubMed ID: 29703539
[No Abstract] [Full Text] [Related]
20. A novel SOS1-ALK fusion variant in a patient with metastatic lung adenocarcinoma and a remarkable response to crizotinib.
Chen HF; Wang WX; Xu CW; Huang LC; Li XF; Lan G; Zhai ZQ; Zhu YC; Du KQ; Lei L; Fang MY
Lung Cancer; 2020 Apr; 142():59-62. PubMed ID: 32114282
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]